Let's start the week with a story hitting close to home. Jury selection starts today in Ottawa for what is sure to a be a complicated, long-lasting, emotionally draining, not to mention historic trial.
The accused in this case is 39-year old Jacques Mungwarere, arrested in 2009 in Windsor for his alleged participation in the 1994 Rwandan Genocide. Mungwarere specifically is accused to have participated in the mass killing in two schools and one hospital.
Monday, April 30, 2012
Justice by Jury?
Friday, April 27, 2012
Justice for Sierra Leone
Advocates of
international justice rejoiced this past Thursday, as some justice has been
delivered to the former leader of the war-torn Liberia , Charles Taylor.
After being on
trial for almost five years, the Special Court for Sierra
Leone (SCSL) found Taylor
guilty on 11 counts including terrorism, rape, slavery, use of child
soldiers and other crimes against humanity. This verdict is significant not
only being it represents the first head of state that has been convicted for atrocities
that occurred in Sierra Leone during the civil war of the 1990s, but also as
Taylor is the first head of state to be convicted of sexual crimes by an international
tribunal.
Labels:
gender justice,
international justice,
Sierra Leone
Saturday, April 21, 2012
At Last, Potential Recognized: Micronutrients
Over the past several decades, micronutrients have never received the same media attention as other global health issues such as HIV/AIDs control or malaria. Yet despite their lack of fame, research in the field has proven repeatedly and consistently that micronutrients contain vital health benefits.
Labels:
Copenhagen Consensus,
Gates Foundation,
micronutrients,
vitamin A,
zinc
Closing the Gap: The Health Impact Fund
To anyone working in global health, the 10-90 gap is a familiar problem. Globally, approximately only 10 percent of spending on health goes towards treating diseases that affect 90 percent of the population. Adding to this disparity is that diseases that contribute most to global rates of morbidity and mortality, such as HIV/AIDS, tuberculosis, and diarrheal diseases, disproportionately affect the poor. What we need is more effective and affordable drugs for these diseases, but the current patent system enforced by TRIPS has proven to be a hindrance in this regard.
Labels:
drug development,
neglected diseases,
new ideas,
TRIPS
Subscribe to:
Posts (Atom)